Healthy Volunteer, Single Ascending Dose Study of TP-317

Phase 1

Completed

Conditions: Inflammatory bowel disease
Oral and Gastrointestinal - Inflammatory bowel disease

Registration Number: ACTRN12624000239561

Lead Sponsor: Thetis Pharmaceuticals LLC

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 24

Inclusion Criteria

1. Males and females aged 18 to 65 years, inclusive at time of signing informed consent form
a. Female participants of childbearing potential may participate but are required to either abstain from sexual intercourse or use two highly effective methods of
contraception during the study, and for at least 30 days after the last dose of study medication.
b. Female participants must not be pregnant or breastfeeding at Screening or during the study period, and for 30 days after the final study drug administration.
c. Male participants with partners of childbearing potential may participate in the study if they had a vasectomy at least 6 months prior to randomization or if adequate contraception is used during the study and for at least 90 days after the last dose of study medication.
d. Sperm donation is prohibited during the study for at least 90 days and ova donation is prohibited during the study for at least 30 days after the last dose of study medication
2. Must meet the following laboratory criteria during Screening
a. Acceptable renal function defined as calculated creatinine clearance 90 mL/min/1.73 m2 or greater by Cockcroft-Gault:
b. Neutrophil count within the normal reference range
c. Platelet count > 100,000 µl
d. Eosinophil count within normal reference range
e. basophil count within normal reference range
f. Hemoglobin > normal reference range
g. PT within normal reference range
h. PTT within normal reference range
i. Serum creatinine within the normal reference range
3. Body Mass Index of 18 – 35 kg/m2 inclusive
4. Must agree to abstain from tobacco and/or cannabis use from Screening visit through safety follow-up visit.
5. Able to swallow numerous pills (i.e., study medication) at one time or in quick succession.
6. Willing and capable of giving written informed consent, which includes being able to comply with all aspects of the study treatment and testing schedule.
7. Will not participate in another interventional study while in this clinical study.

Exclusion Criteria

1. History of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/ substance abuse within past 2 years prior to screening or the participant tests positive at the Screening or upon admission to the CRU for alcohol
2. History of substance abuse or dependency in the last 12 months, or a history of recreational intravenous drug use over the last 5 years (by self-declaration), or a positive toxicology screening panel (urine test including qualitative identification of amphetamines, barbiturates, benzodiazepines, THC, cocaine, and opiates) or positive testing identified by Phase 1-unit standard drug screening panel at Screening Visit or upon admission to study unit
3. Chronic use of cannabis and/or tobacco defined as daily use for greater than 3 months
4. Has greater than 6 months of chronic back pain, Grade 2 or greater, requiring chronic analgesic use, defined as requiring analgesics most days.
5. Any abnormal laboratory test results assessed as clinically significant by the Investigator.
6. Has alkaline phosphatase (ALP), aspartate transaminase (AST) and/or alanine transaminase (ALT) levels or total bilirubin >1.5 × the upper limit of normal (ULN),
Participants with a total bilirubin >2 x ULN that have a documented diagnosis of Gilbert’s syndrome may be enrolled
7. History or presence of any form of cancer within the 5 years prior to screening, with the exception of excised basal cell or squamous cell carcinoma of the skin, or carcinoma in
situ such as cervical or breast carcinoma that has been excised or resected completely and is without evidence of local recurrence or metastasis.
8. Has any medical condition (acute or chronic illness) or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant’s
ability to participate in this study such as but not limited to: Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease. Presence
or history of any significant hemorrhage, thromboembolic diseases or diatheses such as hypercoagulability, platelet disorder, or erythrocytosis.
9. Any surgical procedure (except for procedures determined by the investigator to be minor) within 4 weeks prior to the Screening Visit
10. Use of concomitant medication (including over the counter medication, health supplements, multivitamins and vitamin C, vitamin and omega-3 supplements, and herbal remedies such as St. John’s Wort extract) must be stopped at least 14 days prior to the first dose and not restarted until Day 7
11. Unable to stop use of proton pump inhibitors, H2 -receptor antagonists and antacids for 14 days prior to study drug administration through 7 days post study drug administration
12. Received a live vaccine within 4 weeks prior to Screening visit.
13. Know hypersensitivity to the study drug or it’s excipients thereof, or drug or other allergy that, in the opinion of the Investigator contraindicates participation in the study.
14. Intake of more than 6 cups of coffee or tea or equivalent of caffeinated beverages per day for > 3 months.
15. Positive test for hepatitis B virus (HBsAg), hepatitis C virus (HCV) antibodies, HIV1 or HIV2 at Screening Visit (participants testing positive for Hep B that have been treated be enrolled at investigator discretion)
16. Cannot have donated blood (quantified by 10% of pa